Drug Index

Mepolizumab

 
print

Mechanism :

Mepolizumab is an interleukin-5 antagonist (IgG1 kappa), it thus reduces the production and survival of eosinophils.


Indication :

• Asthma: Add-on maintenance treatment of severe asthma pediatric patients =12 years of age with an eosinophilic phenotype

• Eosinophilic granulomatosis with polyangiitis


Contraindications :

Hypersensitivity to mepolizumab or any component of the formulation.


Dosing :

Asthma:

Children ≥12 years and Adolescents:

Subcutaneous: 100 mg once every 4 weeks.

Eosinophilic granulomatosis with polyangiitis (treatment):

Subcutaneous: 300 mg once every 4 weeks.


Adverse Effect :

Headache, injection site reactions, fatigue, eczema, pruritus, upper abdominal pain, UTI, hypersensitivity reactions, immunogenicity, influenza, back pain, muscle spasm.


Interaction :

No known significant interactions.


07/15/2019 06:40:03 Mepolizumab
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0